Join Ziccum, as CEO Ann Gidner presents the company’s excellent new mRNA/LNP results, generated in both internal and partnered projects, at the mRNA-based Therapeutics Summit Europe 2024 in Berlin.
Ziccum is represented by CEO Ann Gidner and Scientific Director Fabrice Rose. The Ziccum presentation on Wednesday 24 January at 14.15, includes highlights of Ziccum’s recent results confirming LaminarPace’s ability to turn mRNA/LNP liquid biological material into a thermostable dry powder, retaining excellent mRNA activity, requiring no cryogenic handling and highly suited to novel delivery forms such as inhalation.
The presentation is titled ‘A Novel Unit Operation Successfully Drying mRNA/LNP by Mass Transfer’.